Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer.

Black men were more likely not to receive guideline-concordant PSA surveillance testing following definitive treatment for localized prostate cancer during the first 4 years post-treatment. This study suggest room for improvement in defining survivorship care plans for Black men to increase use of PSA surveillance testing.